Literature DB >> 35119668

An Optimized ChIP-Seq Protocol to Determine Chromatin Binding of Estrogen Receptor Beta.

Rajitha Indukuri1,2, Anastasios Damdimopoulos3, Cecilia Williams4,5.   

Abstract

Estrogen regulates transcription through two nuclear receptors, ERα and ERβ, in a tissue and cellular-dependent manner. Both the receptors bind estrogen and activate transcription through direct or indirect interactions with DNA. Revealing their interactions with the chromatin is key to understanding their transcriptional activities and their biological functions. Chromatin-immunoprecipitation followed by sequencing (ChIP-Seq) is a powerful technique to map protein-DNA interactions at precise genomic locations. The genome-wide binding of ERα has been extensively studied. Similar studies of ERβ, however, have been more difficult, in part due to a lack of endogenous expression in cell lines and lack of specific antibodies. In this chapter, we provide an optimized stepwise ChIP protocol for a well-validated ERβ antibody, which is applicable for ChIP-Seq analysis of cell lines with exogenous expression of ERβ.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody; ChIP-Seq; Chromatin binding; Estrogen receptor beta; Immunoprecipitation; Transcription factor

Mesh:

Substances:

Year:  2022        PMID: 35119668     DOI: 10.1007/978-1-0716-1920-9_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  35 in total

1.  A comparison of transcriptional activation by ER alpha and ER beta.

Authors:  S M Cowley; M G Parker
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

2.  Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway.

Authors:  M Jakacka; M Ito; J Weiss; P Y Chien; B D Gehm; J L Jameson
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

3.  ChIP-Seq: Library Preparation and Sequencing.

Authors:  Karyn L Sheaffer; Jonathan Schug
Journal:  Methods Mol Biol       Date:  2016

Review 4.  Mechanisms of estrogen action.

Authors:  S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson
Journal:  Physiol Rev       Date:  2001-10       Impact factor: 37.312

Review 5.  ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions.

Authors:  Terrence S Furey
Journal:  Nat Rev Genet       Date:  2012-10-23       Impact factor: 53.242

Review 6.  ChIP-seq: advantages and challenges of a maturing technology.

Authors:  Peter J Park
Journal:  Nat Rev Genet       Date:  2009-09-08       Impact factor: 53.242

7.  Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing.

Authors:  Gordon Robertson; Martin Hirst; Matthew Bainbridge; Misha Bilenky; Yongjun Zhao; Thomas Zeng; Ghia Euskirchen; Bridget Bernier; Richard Varhol; Allen Delaney; Nina Thiessen; Obi L Griffith; Ann He; Marco Marra; Michael Snyder; Steven Jones
Journal:  Nat Methods       Date:  2007-06-11       Impact factor: 28.547

8.  Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data.

Authors:  Anton Valouev; David S Johnson; Andreas Sundquist; Catherine Medina; Elizabeth Anton; Serafim Batzoglou; Richard M Myers; Arend Sidow
Journal:  Nat Methods       Date:  2008-09       Impact factor: 28.547

9.  Estrogen receptor-dependent activation of AP-1 via non-genomic signalling.

Authors:  Linda Björnström; Maria Sjöberg
Journal:  Nucl Recept       Date:  2004-06-14

10.  Global analysis of in vivo Foxa2-binding sites in mouse adult liver using massively parallel sequencing.

Authors:  Elizabeth D Wederell; Mikhail Bilenky; Rebecca Cullum; Nina Thiessen; Melis Dagpinar; Allen Delaney; Richard Varhol; YongJun Zhao; Thomas Zeng; Bridget Bernier; Matthew Ingham; Martin Hirst; Gordon Robertson; Marco A Marra; Steven Jones; Pamela A Hoodless
Journal:  Nucleic Acids Res       Date:  2008-07-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.